Taking COL1A1 promotor as the biomarker, a luciferase screening cell model based on the elevation effect of TGF-β1 upon the expression of COL1A1 promoter was established earlier in our group [13], and successfully applied to the screening and evaluation of anti-hepatic fibrosis drug candidates [14,15,16]. This evidence concerns the gene COL1A1 and Hepatic fibrosis.